Disputes & ADR - Lawyer Monthly https://www.lawyer-monthly.com Legal News Magazine Mon, 09 Mar 2026 09:34:17 +0000 en-GB hourly 1 https://wordpress.org/?v=6.9.1 https://www.lawyer-monthly.com/wp-content/uploads/2025/09/cropped-favicon-32x32.jpg Disputes & ADR - Lawyer Monthly https://www.lawyer-monthly.com 32 32 UK Supreme Court Rejects Spain’s Sovereign Immunity Defence in €101M Investment Arbitration Case https://www.lawyer-monthly.com/2026/03/uk-supreme-court-rejects-spains-sovereign-immunity-defence-in-e101m-investment-arbitration-case/ Mon, 09 Mar 2026 09:34:17 +0000 https://www.lawyer-monthly.com/?p=92004 The Supreme Court of the United Kingdom has ruled that foreign states cannot rely on sovereign immunity to block the enforcement of arbitration awards issued under the ICSID Convention.

In Infrastructure Services Luxembourg S.à.r.l and another v Kingdom of Spain, decided on 4 March 2026, the Court unanimously dismissed Spain’s appeal and confirmed that ICSID awards can be registered and enforced in the United Kingdom without states invoking immunity to prevent the process.

The ruling clarifies how the State Immunity Act 1978 interacts with the UK’s obligations under the Arbitration (International Investment Disputes) Act 1966.

For investors and arbitration practitioners, the judgment reinforces London’s role as a jurisdiction where treaty arbitration awards can be recognised even when sovereign respondents resist enforcement.

The Dispute

The case arose from investment arbitration proceedings brought by Infrastructure Services Luxembourg S.à.r.l and Energia Termosolar B.V. against Spain.

The investors alleged that regulatory changes affecting Spain’s renewable-energy support regime breached the country’s obligations under international investment law.

An arbitral tribunal constituted under the ICSID framework ruled in favour of the investors and awarded approximately €101 million in compensation.

The investors then applied to register the award in England under the Arbitration (International Investment Disputes) Act 1966, which implements the UK’s obligations under the ICSID Convention.

Spain sought to have the registration set aside, arguing that as a sovereign state it was protected by immunity under the State Immunity Act 1978 and could not be subjected to enforcement proceedings in English courts.

The dispute had previously reached the Court of Appeal, which rejected Spain’s argument and held that participation in the ICSID Convention entails acceptance that awards may be recognised and enforced in other contracting states.

Spain appealed that decision to the UK Supreme Court.

The appeal was heard together with a related case involving Republic of Zimbabwe v Border Timbers Ltd, which raised similar issues concerning sovereign immunity and the enforcement of ICSID arbitration awards.

What the Court Decided

The Supreme Court dismissed Spain’s appeal.

The Court held that a state that has agreed to the ICSID Convention cannot rely on sovereign immunity to prevent the registration of an ICSID arbitration award in the courts of another contracting state.

The justices concluded that registering an ICSID award under the Arbitration (International Investment Disputes) Act 1966 does not involve a substantive determination of the dispute by the court.

Instead, the registration process is a procedural step required by the Convention to give effect to the award.

Because the court does not reconsider the merits of the underlying dispute, the process does not constitute the type of judicial determination from which sovereign immunity would normally protect a foreign state.

The ruling therefore upheld the earlier judgment of the Court of Appeal and confirmed that the investors were entitled to register the €101 million award in England.

How the Court Got There

The case required the Court to interpret the relationship between two legal frameworks: the ICSID Convention, which establishes a global system for investor–state arbitration, and the State Immunity Act 1978, which governs when foreign states can be subject to the jurisdiction of UK courts.

Article 54 of the ICSID Convention requires contracting states to recognise ICSID awards as binding and enforce them as if they were final judgments of their own courts.

Spain argued that this obligation did not amount to consent to domestic court proceedings and that sovereign immunity should therefore prevent enforcement in the UK.

The investors argued that participation in the ICSID system necessarily involves acceptance that domestic courts in other member states will play a limited role in recognising and enforcing awards.

The Supreme Court agreed with the investors’ position. It held that the ICSID Convention creates a self-contained enforcement regime in which national courts perform a narrowly defined administrative function when registering awards.

Because the courts do not re-examine the underlying dispute, the process does not engage the core concerns that sovereign immunity is intended to protect.

Why the Ruling Matters

For investors pursuing claims against states under bilateral investment treaties, arbitration awards are only meaningful if they can ultimately be enforced.

States sometimes resist payment even after losing arbitration, forcing investors to seek recognition of awards in national courts around the world.

The Supreme Court’s decision confirms that English courts will give effect to the ICSID enforcement framework established by treaty and implemented in domestic legislation.

The ruling therefore reinforces the UK’s position as an important jurisdiction for the enforcement of international arbitration awards.

Separate Opinions

The appeal was heard by a panel consisting of Lord Lloyd-Jones, Lord Briggs, Lord Sales, Lord Leggatt and Lady Simler.

The Court delivered a unanimous judgment dismissing Spain’s appeal.

What Happens Next

Following the Supreme Court’s ruling, the investors remain entitled to rely on the registered arbitration award in England.

The judgment resolves Spain’s attempt to invoke sovereign immunity to prevent the registration of the ICSID award under UK law.

More broadly, the decision confirms that ICSID arbitration awards can be registered and enforced in English courts and that states party to the ICSID Convention cannot rely on sovereign immunity to block that process.

Case details

Court: Supreme Court of the United Kingdom
Date: 4 March 2026
Case: Infrastructure Services Luxembourg S.à.r.l and another v Kingdom of Spain
Neutral citation: [2026] UKSC 9
Docket number: UKSC/2024/0155
Area of law: International arbitration / sovereign immunity
Result: Spain’s appeal dismissed

People Also Ask

What is the ICSID Convention?
The ICSID Convention is an international treaty that establishes a system for resolving disputes between foreign investors and states through arbitration. Awards issued under the Convention are enforceable in all contracting states.

What did the UK Supreme Court decide in Infrastructure Services v Spain?
The Court ruled that Spain could not rely on sovereign immunity to challenge the registration of an ICSID arbitration award in England. The appeal was dismissed and the award remained enforceable.

Why are ICSID arbitration awards important?
ICSID awards allow investors to recover damages when states breach investment treaty obligations. The Convention ensures those awards can be recognised and enforced across member states.

What is sovereign immunity under UK law?
Sovereign immunity is a principle under the State Immunity Act 1978 that generally protects foreign states from being sued in UK courts, subject to certain exceptions.

Why does this ruling matter for international arbitration?
The decision confirms that English courts will recognise and enforce ICSID awards against states that are parties to the Convention, strengthening London’s role in the global arbitration system.

]]> Supreme Court Rules NJ Transit Not Entitled to Interstate Sovereign Immunity https://www.lawyer-monthly.com/2026/03/supreme-court-nj-transit-interstate-sovereign-immunity/ Thu, 05 Mar 2026 09:55:50 +0000 https://www.lawyer-monthly.com/?p=91948 The U.S. Supreme Court has ruled that the New Jersey Transit Corporation is not entitled to interstate sovereign immunity, allowing negligence lawsuits against the transit operator to proceed in other states’ courts.

In Galette v. New Jersey Transit Corporation, the Court held that the state-created transit authority does not qualify as an arm of the State of New Jersey for purposes of constitutional sovereign immunity.

The ruling resolves conflicting decisions from the highest courts of Pennsylvania and New York and clarifies how courts determine whether state-created corporations share in a state’s immunity from suit under the Federal Constitution.

The Dispute in Brief

The litigation arose from a negligence lawsuit brought by Cedric Galette following a vehicle collision involving a New Jersey Transit bus.

According to the petition filed with the Supreme Court, Galette alleged that on August 9, 2018, he was a passenger in a vehicle stopped on Market Street in Philadelphia when a New Jersey Transit bus struck the car, causing injuries.

Galette sued both New Jersey Transit and the driver of the vehicle, alleging that their separate acts of negligence caused the accident.

New Jersey Transit moved to dismiss the lawsuit, arguing that it is an arm of the State of New Jersey and therefore entitled to interstate sovereign immunity when sued in the courts of another state.

Lower courts in Pennsylvania initially allowed the lawsuit to proceed. The Pennsylvania Supreme Court later reversed those rulings, concluding that the transit authority qualified as an arm of the state and therefore enjoyed sovereign immunity from the suit.

The case reached the U.S. Supreme Court after conflicting rulings from the highest courts of Pennsylvania and New York on the same constitutional question.

The Supreme Court’s Decision

The Supreme Court held that New Jersey Transit does not qualify as an arm of the State of New Jersey for purposes of interstate sovereign immunity.

As a result, the Court affirmed the judgment of the New York Court of Appeals, which had allowed a lawsuit against the transit authority to proceed, and reversed the judgment of the Pennsylvania Supreme Court, which had dismissed Galette’s lawsuit.

Both cases were remanded for further proceedings consistent with the Court’s ruling.

In reaching that conclusion, the Court explained that sovereign immunity belongs to the state itself and extends only to entities that function as an “arm of the State.”

Determining whether an entity qualifies requires examining how the state structured the organisation under its laws, including its legal status, operational autonomy, and financial relationship with the state.

Under New Jersey law, the New Jersey Transit Corporation was created as a separate corporate entity with powers typical of an independent public corporation, including the authority to sue and be sued, enter contracts, acquire property, and manage its own affairs.

The Court also emphasised that New Jersey law specifies that the corporation’s debts and liabilities are not obligations of the state treasury.

Because a judgment against New Jersey Transit would not be paid by the State of New Jersey itself, the Court concluded that this factor strongly weighs against treating the transit authority as part of the state.

Although New Jersey exercises oversight over the organisation, including appointing board members and retaining certain supervisory powers — the Court said such control does not change the corporation’s legally independent status.

Taken together, the Court concluded that New Jersey structured the transit authority as a separate corporation responsible for its own liabilities rather than as an alter ego of the state government.

Key Legal Takeaways

The decision clarifies that state-created corporations will not automatically qualify as an “arm of the State” for purposes of interstate sovereign immunity.

In determining whether an entity shares a state’s constitutional immunity, courts will examine how the entity is structured under state law, including its legal status, operational autonomy and financial relationship with the state.

The Court placed particular emphasis on whether the state treasury would be responsible for judgments against the entity.

The ruling may affect litigation involving other state-created authorities and public corporations operating across state lines.

What Happens Next

The Supreme Court remanded the cases for further proceedings.

As a result, the negligence claims brought by the plaintiffs may now proceed in the courts where they were originally filed.

Case details

Court: Supreme Court of the United States
Date: March 4, 2026
Case: Galette v. New Jersey Transit Corporation
Docket number: 24-1021
Area of law: Constitutional law / sovereign immunity
Result: Pennsylvania Supreme Court reversed; New York Court of Appeals affirmed; cases remanded

]]> Kevin Spacey Set to Testify in $100M House of Cards Insurance Trial https://www.lawyer-monthly.com/2026/03/kevin-spacey-house-of-cards-insurance-trial/ Mon, 02 Mar 2026 10:53:37 +0000 https://www.lawyer-monthly.com/?p=91812 A high-stakes coverage dispute between Media Rights Capital and Fireman’s Fund will turn on whether Kevin Spacey’s absence from House of Cards season six qualifies as a covered “sickness” loss.

A U.S. jury is preparing to hear evidence in a closely watched insurance battle that could determine whether losses tied to the show’s final season are recoverable under a production policy.

Media Rights Capital (MRC), the studio behind the Netflix political drama, is seeking approximately $100 million from its insurer, Fireman’s Fund Insurance Company.

The company argues that Spacey was medically unable to continue filming in 2017 and that the resulting disruption triggered coverage.

The Dispute in Brief

The litigation represents what has been described as MRC’s third and likely final attempt to recover losses associated with the show’s sixth season.

The production company contends that Spacey’s unavailability, following allegations of sexual misconduct that emerged in late 2017, should be treated as a covered “sickness” event under its policy.

Spacey, now 66, is expected to testify in support of MRC’s position. His cooperation reportedly follows an agreement by the production company to reduce a prior arbitration award against him from $31 million to $1 million.

That earlier award stemmed from contractual disputes after the actor was removed from the series.

According to reports cited in court coverage, further details of Spacey’s anticipated testimony remain sealed.

The Legal Fault Lines

At the centre of the case is a familiar but complex insurance question: what constitutes a covered loss when a production is disrupted by circumstances involving a key performer.

MRC’s policy reportedly covered losses linked to an actor’s “sickness.” The company’s position is that Spacey was genuinely unable to perform due to an alleged sex addiction and related treatment following the 2017 allegations.

If accepted, that framing could bring the claim within the policy’s coverage trigger.

Fireman’s Fund disputes that characterisation. The insurer argues that the financial damage flowed primarily from reputational fallout and business decisions, including the suspension of Spacey, rather than from any qualifying medical incapacity.

If a jury agrees with that view, the losses may fall outside the policy’s scope.

The case therefore turns heavily on causation: whether the proximate driver of the production losses was illness or the corporate response to public controversy.

Competing Arguments

MRC is expected to present evidence that Spacey could not and should not have returned to work at the time, and that his treatment and condition rendered him unavailable for filming.

The company has also pointed to communications in early November 2017 suggesting the actor was “sick” and would be away for an extended period.

However, the insurer is likely to focus on conflicting contemporaneous statements. Reports indicate that shortly after the “sick” representation was made, a lawyer for Spacey advised MRC that the actor was “available, willing and able” to fulfil his contractual obligations. That apparent discrepancy may become a central issue for jurors assessing credibility and causation.

Fireman’s Fund’s broader position is that MRC’s losses stemmed from the media and commercial fallout following the misconduct allegations, and that any suspension of Spacey was ultimately a business decision rather than the unavoidable consequence of medical incapacity.

Why This Case Matters

The dispute carries significance well beyond a single television series. Production insurance policies are a cornerstone of film and television financing, and coverage battles involving key talent can expose gaps in risk allocation.

For insurers, the case tests how narrowly courts and juries will interpret “sickness” triggers where reputational crises and health claims overlap.

For studios and financiers, the outcome may influence how future policies are drafted, particularly around morality clauses, availability provisions and exclusions tied to misconduct allegations.

The litigation also illustrates the strategic interplay between arbitration outcomes and subsequent insurance recovery efforts — an area of growing attention in entertainment-sector disputes.

What the Jury Must Decide

Jurors will be asked to weigh whether Spacey was in fact medically unable to perform and whether that condition, rather than reputational or business considerations was the proximate cause of the claimed losses.

They may also examine Netflix’s contractual role. Under the show’s distribution arrangements, the streamer reportedly held certain “tiebreaker” rights over scripts, storylines and casting, and the parties dispute how, or whether, those rights were exercised following the 2017 allegations.

The trial’s outcome will determine whether MRC can recover nine-figure damages under the policy or whether the losses remain with the production company.

Given the high stakes and the fact-intensive nature of the dispute, the verdict could become an important reference point for future entertainment insurance litigation.

]]>